Eli Lilly and Co (LLY)
767.76
+10.22
(+1.35%)
USD |
NYSE |
Dec 20, 16:00
780.00
+12.24
(+1.59%)
After-Hours: 20:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 728.85B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 35.52% |
Valuation | |
PE Ratio | 83.00 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 16.99 |
Price to Book Value | 51.18 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | 1.50 |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 2.185 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 24.12% |
Profile
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. |
URL | https://www.lilly.com |
Investor Relations URL | https://investor.lilly.com/ |
HQ State/Province | Indiana |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | Large Cap/Growth |
Next Earnings Release | May. 01, 2025 |
Last Earnings Release | Oct. 30, 2024 |
Next Ex-Dividend Date | Feb. 14, 2025 |
Last Ex-Dividend Date | Nov. 15, 2024 |
Ratings
Profile
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. |
URL | https://www.lilly.com |
Investor Relations URL | https://investor.lilly.com/ |
HQ State/Province | Indiana |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | Large Cap/Growth |
Next Earnings Release | May. 01, 2025 |
Last Earnings Release | Oct. 30, 2024 |
Next Ex-Dividend Date | Feb. 14, 2025 |
Last Ex-Dividend Date | Nov. 15, 2024 |